6185 (6185) Fair Value & Analysis

Healthcare · Market cap HK$5.8B

6 6185 6185 · HK

PriceHK$23.20

Fair ValueHK$9.54

Upside-58.9%

Quality42/100

Watch 6185 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$6.30 – HK$13.44

Fair value as of: Jul 2, 2026

From 12 valuation models · updated today

Share price −8.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$20.96 – HK$55.50 · fair‑value band HK$6.30 – HK$13.44 · the HK$23.20 price screens above the HK$9.54 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6185 (6185) currently trades at HK$23.20, while our model-based Fair Value estimate is HK$9.54 — implying the stock looks roughly 58.9% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 6185 generated revenue of HK$1.1B at a net margin of -0.1%. Revenue grew 38.7% year over year. Net debt stands at HK$52.8M. The stock trades on a trailing P/E of 179.8. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.1B

Revenue growth (YoY) +38.7%

Net margin -0.1%

Return on equity 0.0%

Free cash flow −HK$153M FY2025

P/E ratio 179.8

More key figures

Operating margin -15.2%

EPS (TTM) HK$0.1394

EPS growth (YoY) +1,169%

Net debt HK$52.8M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6185 reported revenue of HK$1.0B in FY2025 versus HK$4.3B in FY2021, a compound −30.0%/yr. Reported net income was HK$27.2M in FY2025, compounding −65.5%/yr from FY2021.

Revenue −30.0%/yr

FY21 HK$4.3B

FY22 HK$1.0B

FY23 HK$345M

FY24 HK$846M

FY25 HK$1.0B

Net income −65.5%/yr

FY21 HK$1.9B

FY22 −HK$909M

FY23 −HK$1.5B

FY24 −HK$379M

FY25 HK$27.2M

Is 6185 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.01	¥26.59	-43%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6185 (6185) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$9.54 versus a price of HK$23.20 — about −59% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6185?

Our model-based fair value for 6185 is HK$9.54 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$23.20.

What is the quality score of 6185?

6185 has a Quality Score of 42/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6185 (6185)?

6185 reported trailing-twelve-month revenue of about HK$1.1B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6185?

The net profit margin of 6185 is about -0.1%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.